T-NeuroDx

About

Built from the biology that drives Alzheimer's, not the pathology it leaves behind.

T-NeuroDx is a diagnostics company developing the AlzheimerGuard hiT Cell™ assay, a blood-based test that identifies disease-causing immune cells implicated in the causation and progression of Alzheimer's Disease (AD). The company holds an exclusive global commercial license from Cedars-Sinai Medical Center on IP developed by its CSO and Scientific Co-Founder, Dr. Chris Wheeler. T-NeuroDx has established strategic partnerships with Beckman Coulter and TrilliumBiO, secured a $500,000 NIH SBIR Phase 1 grant, and published their foundational science in PNAS demonstrating the hiT Cell’s ability to induce Alzheimer’s-like pathology in mice and a human blood assay demonstrating an AUC of 0.87 to 0.89 across two independent clinical cohorts totaling 157 patients.

The Alzheimer's diagnostic biomarker landscape is dominated by assays that detect amyloid or tau pathology. None is based on a mechanistic biomarker and none can predict an individual’s likelihood of progressing to disease. Only 30% of amyloid-positive cognitively normal individuals will develop Alzheimer's dementia in their lifetime. This inability to detect disease early has led to >99% of drug trials failing and immense diagnostic uncertainty for physicians. The hiT Cell assay detects the only biomarker causally linked to disease progression and is a mechanistic complement to existing amyloid-tau panels, not a competitor.